Avior Wealth Management’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-170
Closed -$13.3K 1416
2024
Q4
$13.3K Buy
170
+9
+6% +$723 ﹤0.01% 1530
2024
Q3
$12.9K Buy
161
+109
+210% +$8.81K ﹤0.01% 1477
2024
Q2
$4.3K Sell
52
-10
-16% -$880 ﹤0.01% 1767
2024
Q1
$5.29K Buy
62
+36
+138% +$2.83K ﹤0.01% 2066
2023
Q4
$2.22K Sell
26
-17
-40% -$1.47K ﹤0.01% 1291
2023
Q3
$3.85K Hold
43
﹤0.01% 1266
2023
Q2
$3.66K Buy
+43
New +$3.63K ﹤0.01% 1261
2022
Q1
Sell
-5,734
Closed -$304K 1155
2021
Q4
$304K Hold
5,734
0.03% 389
2021
Q3
$404K Buy
+5,734
New +$362K 0.03% 348
2020
Q2
Sell
-1,830
Closed -$182K 937
2020
Q1
$182K Sell
1,830
-1,530
-46% -$166K 0.04% 356
2019
Q4
$386K Buy
3,360
+840
+33% +$102K 0.06% 268
2019
Q3
$317K Hold
2,520
0.06% 287
2019
Q2
$303K Sell
2,520
-280
-10% -$27.5K 0.05% 294
2019
Q1
$244K Sell
2,800
-696
-20% -$63.3K 0.05% 315
2018
Q4
$349K Buy
3,496
+1,058
+43% +$111K 0.08% 221
2018
Q3
$279K Buy
2,438
+548
+29% +$56.7K 0.06% 274
2018
Q2
$169K Sell
1,890
-1,412
-43% -$119K 0.04% 365
2018
Q1
$242K Sell
3,302
-1,155
-26% -$79.2K 0.06% 268
2017
Q4
$259K Buy
+4,457
New +$235K 0.06% 273

Other funds holding HAE

Avior Wealth Management's HAE Position: Q1 2025 in Review

Avior Wealth Management sold out of Haemonetics (HAE) in Q1 2025, closing a stake of 170 shares — an estimated $13.3K sold.

Avior Wealth Management first reported a position in HAE in Q4 2017 and held it in 19 quarters. The position peaked at $404K in Q3 2021. 314 funds tracked by Wall St. Rank hold HAE as of Q1 2025.

  • Avior Wealth Management reported no remaining Haemonetics position as of Q1 2025 after selling out during the quarter.
  • Avior Wealth Management sold 170 Haemonetics shares in Q1 2025, an estimated $13.3K.
  • Avior Wealth Management first reported a position in Haemonetics in Q4 2017 and held it in 19 quarters.
  • Avior Wealth Management's Haemonetics position peaked at $404K in Q3 2021.
  • 314 funds tracked by Wall St. Rank held Haemonetics as of Q1 2025.

Based on Avior Wealth Management's 13F filing for Q1 2025, filed 21 Apr 2025.